Author

W. G. Wierda

Observed name: William G. Wierda

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

OpenAlex ID: A5082576312

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

2016 · C. Vitale, I. E. Ahn, et al. · Haematologica · 46

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

2015 · Anders Österborg, Roxanne C. Jewell, et al. · Haematologica · 21

S146: Venetoclax in Patients With Chronic Lymphocytic Leukemia With 17p Deletion: 6-year Follow-up and Genomic Analyses in a Pivotal Phase 2 Trial

2022 · S. Stilgenbauer, E. Tausch, et al. · HemaSphere · 6

P649: a First-in-human Phase 1 Trial of Nx-2127, a First-in-class Oral Btk Degrader With Imid-like Activity, in Patients With Relapsed and Refractory B-cell Malignancies

2022 · A. Mato, A. Danilov, et al. · HemaSphere · 5

P356: Subgroup Analyses of Kte-x19, an Anti-cd19 Chimeric Antigen Receptor (car) T-cell Therapy, in Adult Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-all) in Zuma-3

2022 · B. D. Shah, R. D. Cassaday, et al. · HemaSphere · 4

P666: Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-naive Chronic Lymphocytic Leukemia: 5-year Follow-up of Elevate-tn

2022 · J. P. Sharman, M. Egyed, et al. · HemaSphere · 4

UVI5008: the first reversible, non-covalent Bruton’s tyrosine kinase epi-inhibitor for B-cell malignancies

2026 · Carmela Dell’Aversana, G. Sgueglia, et al. · Journal of Hematology & Oncology

Works count: 7

Citation count: 86

H-index: 4

I10-index: 2